Sermorelin Before and After: The Timeline the Trial Data Support

Search "sermorelin before and after" and you get clinic photographs, six-week transformation posts and almost no numbers. That is odd, because sermorelin has a longer clinical record than most research peptides. It was approved as Geref for paediatric growth hormone deficiency, it ran through controlled trials in older adults in the early and mid 1990s, and those trials measured IGF-1, DEXA body composition, skin thickness, lipids and sleep. The results are more interesting than the photographs, partly because one of the best-run studies found nothing at all.

This page sets out what the published data record week by week, why two studies of the same compound in similar men reached opposite conclusions, what dose the positive results were actually built on, and what a researcher should log before the first injection so that their own "after" means something. The sermorelin dosage guide covers the protocols and the reconstitution arithmetic; this page is only about the timeline and the evidence behind it.

Where the sermorelin before-and-after data come from

Four studies carry most of the weight. First, a 1992 dose-finding study in 10 healthy men with a mean age of 68, comparing 0.5 mg and 1 mg of GHRH(1-29) injected twice daily for 14 days against a young control group. Second, a 1997 study of 11 healthy men aged 64 to 76 with low baseline IGF-1, given 2 mg as a single nightly injection for six weeks with DEXA scans and muscle biopsies. Third, the longest of them, a 16-week study of 9 men and 10 women aged 55 to 71 dosed at 10 mcg per kilogram nightly after a four-week placebo run-in. Fourth, the paediatric Geref programme, dosing 30 mcg per kilogram subcutaneously at bedtime in children with a stimulated GH below 10 mcg per litre.

Two things to hold on to before the numbers. Every one of these trials measured IGF-1 as the primary readout, not weight or waist, because IGF-1 is the hormone that actually mediates whatever growth hormone does downstream. And the adult trials enrolled people in their sixties with an already blunted GH axis, which is the population where a secretagogue has the most room to work. A 32-year-old with a normal IGF-1 is outside every dataset on this page.

The week-by-week timeline

The shape of that table is the point. Sermorelin produces a fast hormonal signal and a slow, modest and partly sex-specific tissue response. Anyone judging it on a four-week photograph is measuring the wrong thing at the wrong time.

The study that found nothing, and why it matters

The six-week trial is the most useful negative result in the sermorelin literature, and it is almost never cited in the marketing. Eleven healthy men aged 64 to 76 were selected specifically because their IGF-1 was low, which is the ideal population for a secretagogue. They self-injected 2 mg nightly for six weeks. Their overnight GH release went up significantly. Their IGF-1 did not move. Neither did IGFBP-3 or GH binding protein. DEXA showed no change in fat or muscle, and muscle biopsies showed no histological change.

There are two credible readings, and they are not mutually exclusive. One is schedule: a single nightly injection produces one amplified pulse, and the rest of the 24-hour period looks exactly as it did before, which may not be enough integrated GH exposure to shift hepatic IGF-1 production. The 14-day study that did raise IGF-1 used twice-daily dosing. The other reading is duration: six weeks may simply be short. The 16-week trial saw IGF-1 move by week two, which argues against that, but it also used a weight-adjusted dose in a slightly younger cohort.

Either way, the practical conclusion is the same. A sermorelin protocol that has run six weeks without an IGF-1 check has produced no information at all. That is the difference between a before and after and a story.

The dose gap nobody mentions

Here is the arithmetic that explains most disappointing sermorelin logs. The 16-week trial, the only adult study that moved body composition, dosed 10 mcg per kilogram nightly. For an 80 kg adult that is 800 mcg per injection. For a 100 kg adult it is 1,000 mcg. The paediatric Geref protocol was higher still at 30 mcg per kg.

Common research protocols run 200 to 500 mcg at bedtime. At 80 kg, a 300 mcg dose is 3.75 mcg per kg, a little over a third of what the positive trial used. It is entirely possible to run sermorelin correctly, consistently, for four months, at a dose that no study has ever shown to do anything, and then conclude that the compound does not work. It might just as easily mean the protocol was underdosed.

This is also where the cost picture changes. A 10 mg vial at $59.99 covers roughly 33 injections at 300 mcg but only about 12 at 800 mcg, which moves a trial-equivalent protocol from a cheap experiment into something closer to the numbers in the peptide therapy cost breakdown. Whether that trade is worth it is a judgement, but it should be made with the figures visible rather than by accident.

What to record before the first dose

Sermorelin's effects are hormonal before they are visible, so the baseline log matters more here than for a compound where the scale does the work. Record these on the same weekday, in the morning, fasted.

• IGF-1. The single most important number. It is the readout every trial used, it moves within two weeks when the protocol is working, and without a baseline a follow-up value is uninterpretable.
• Fasting lipid panel. Transient hyperlipidemia was the only adverse effect reported in the 16-week trial, and it resolved before the study ended. Knowing your starting point turns an alarming week-8 panel into an expected one.
• Fasting glucose. Growth hormone opposes insulin. Sermorelin works within the pituitary feedback loop and does not carry the glucose signal that tesamorelin's label does, but a baseline costs nothing.
• Waist circumference at the navel, same tape, three readings averaged, plus a seven-day rolling scale weight. Neither moved in the adult trials, so treat them as a check on diet rather than as evidence about the compound.
• Standardised photographs and a subjective log for well-being and libido, which were the endpoints that improved in men at 16 weeks. Subjective, but they were formally measured and they did move.

What is noise

Sleep improving in week one. This is the most repeated sermorelin claim and the one the controlled data contradict directly. Sleep quality was assessed in the 16-week trial and was unaffected in both men and women. The claim likely comes from the fact that sermorelin amplifies the GH pulse that occurs during early slow-wave sleep, which is a real mechanism that did not translate into measured sleep quality.

Scale weight in the first month. No adult sermorelin trial found a weight change at any timepoint. A kilogram in either direction over four weeks is food and water.

Injection site reactions read as potency. Local redness is a formulation and technique issue, covered in the injection guide, and tells you nothing about systemic effect.

Strength gains without body composition change. The six-week study found improvement in two of several lifts with no DEXA or histological change underneath. Two lifts improving over six weeks of training is what six weeks of training does.

How sermorelin compares on this specific question

Against tesamorelin, sermorelin has far weaker before-and-after evidence. Tesamorelin ran two placebo-controlled phase 3 trials with CT-measured visceral fat endpoints and a published washout arm; sermorelin has one 16-week study with a lean mass finding in nine men. Against ipamorelin, sermorelin has the better clinical record but the shorter half-life and the weaker single-pulse amplitude, which is exactly why the two are so often paired. The sermorelin versus GHRP-6 comparison covers the GHRH plus GHRP logic, and the broader peptides before and after overview puts these timelines side by side across compound classes.

For anyone whose interest is body composition rather than the GH axis specifically, it is worth reading natural GH boosters first, because sleep, training and protein intake move the same axis and cost nothing.

Sourcing notes

Sermorelin is a 29-amino-acid peptide with a short half-life and it degrades quickly if it is handled or stored badly, which matters more than usual here because the trial-relevant effect depends on consistent nightly dosing over sixteen weeks rather than on a single impressive dose. A vendor with a per-batch certificate of analysis is worth more than a few dollars a vial across a protocol that long.

The Bureau's top-scored source for sermorelin is Amino Club at $59.99 for a 10 mg vial, which is the lowest price per milligram of the four vendors we track for this compound. Sermorelin 10mg · $59.99 Compare at Pantheon

The Amino Club review sets out how the scorecard treats it, and how to reconstitute peptides covers getting an 800 mcg draw out of a 10 mg vial without wasting half of it.

Sermorelin is a research compound. The trials described above studied a licensed drug in specific patient populations, mostly adults in their sixties with a blunted GH axis. Nothing here is medical advice, and the Bureau does not advise anyone on using research compounds.

Frequently Asked Questions

How long does sermorelin take to show results?

IGF-1 is the first thing that moves, and in the 16-week trial of adults aged 55 to 71 it was already up within two weeks of nightly dosing. Body composition took far longer: lean body mass changed at the 16-week mark and only in the men. Skin thickness also moved by 16 weeks in both sexes. There is no published sermorelin trial showing a measurable body composition change before three months, so anyone assessing a before and after at week 4 is reading noise.

Why did one sermorelin study find no change at all?

Because of dose and schedule. The 6-week study in 11 healthy men aged 64 to 76 gave 2 mg as a single nightly injection. Nocturnal GH release rose significantly, but IGF-1, IGFBP-3 and GHBP did not change, and neither did weight, BMI, waist to hip ratio, DEXA muscle and fat, or muscle histology. The trials that did move IGF-1 used either 10 mcg per kg nightly for 16 weeks or 1 mg twice daily. A GH pulse that is bigger but still brief does not necessarily raise the downstream hormone that actually drives tissue change.

What does the research dose work out to in micrograms?

The 16-week study dosed 10 mcg per kilogram nightly. For an 80 kg adult that is 800 mcg per injection, and for a 100 kg adult it is 1,000 mcg. Common research protocols run 200 to 500 mcg at bedtime, which is roughly a quarter to a half of the dose that produced the lean mass and skin findings. That gap is the single most useful number on this page, because most disappointing before and after logs are running well under the dose the evidence was built on.

Does sermorelin improve sleep?

The controlled data say no, which contradicts the most common claim made for it. In the 16-week trial, sleep quality was formally assessed and was unaffected in both men and women, while well-being and libido improved in men only. Sermorelin does amplify the nocturnal GH pulse, and that is presumably where the sleep claim originated, but a bigger pulse during slow-wave sleep is not the same as measurably better sleep.

What should I record before the first injection?

IGF-1 first, because it is the only marker that reliably moves early and the only way to tell a working protocol from a dead one. Then a fasting lipid panel, since transient hyperlipidemia was the one adverse finding in the 16-week trial and it resolved on its own. Then fasting glucose, waist circumference at the navel averaged over three readings, a seven-day rolling scale weight, and standardised photographs. Book the IGF-1 draw before the first dose rather than in week three.

Does the effect last after stopping sermorelin?

There is no published washout data for sermorelin the way there is for tesamorelin, so the honest answer is that nobody has measured it. What is known is the mechanism: sermorelin amplifies pituitary output only while it is present and does nothing structural, so the expectation should be that IGF-1 returns to baseline within weeks of the last injection. Any lasting change would come from what was done with the training and food during the cycle, not from the compound.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.